About Bruck Pharma Private Limited
Data last updated: 09 January 2026
Bruck Pharma Private Limited is a private limited company based in Goregaon East, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 23 August 1984, the company has been in operation for over 42 years.
Registered with ROC Mumbai under CIN U24239MH1984PLC416799.
Capital: an authorised share capital of ₹5 Cr and a paid-up capital of ₹2.68 Cr. Formerly known as Brucke Pharma Pvt Ltd and Bruck Pharma Private Limited. It is led by directors Shirish Devendra Kejriwal and Anshu Devendra Kejriwal.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Goregaon East, Maharashtra.
As per the financials filed for FY 2024, the company reported a revenue of ₹58.81 Cr, a growth of 3% compared to the previous year.
The company has a workforce of approximately 123 employees as per the latest available data.
As per MCA filings, the company has open charges of ₹21.03 Cr and satisfied charges of ₹7.1 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bruck.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressOffice No.405 4Th Floor B Wing Cello Triumph, I B Patel Road, Goregaon East, Maharashtra, India – 400063
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Bruck Pharma Private Limited
Bruck Pharma Private Limited has undergone 2 name changes throughout its history. The company was previously known as Brucke Pharma Pvt Ltd, and Bruck Pharma Private Limited. The current legal name is Bruck Pharma Private Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Bruck Pharma Private Limited | Current |
| Brucke Pharma Pvt Ltd | Previous |
CIN History of Bruck Pharma Private Limited
Bruck Pharma Private Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24239MH1984PTC416799, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239MH1984PTC416799 | Current |
| U24239MH1984PLC416799 | Previous |
| U24239WB1984PTC037865 | Previous |
Business Activity of Bruck Pharma Private Limited
Bruck Pharma Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Bruck Pharma Private Limited
Bruck Pharma Private Limited is audited by Priyavrat & Associates for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Priyavrat & Associates | blur-value | blur-value | blur-value |
Board of Directors of Bruck Pharma Private Limited
Bruck Pharma Private Limited is currently managed by 2 directors, with 11 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Shirish Devendra Kejriwal
Also directs:
Bruck Pharma Private Limited, Brucke Biocare Private Limited
|
Director | 25 May 2009 | 17 Years 1 Months | Current |
|
Anshu Devendra Kejriwal
Also directs:
Bruck Pharma Private Limited, Brucke Biocare Private Limited
|
Director | 02 Jul 2010 | 16 Years 0 Months | Current |
Financials of Bruck Pharma Private Limited FY 2025 filings available
Bruck Pharma Private Limited reported revenue of ₹58.81 Cr (up 3% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Bruck Pharma Private Limited
As of FY 2023, Bruck Pharma Private Limited's shareholding pattern shows 92.91% by promoters, 7.08% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Bruck Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Aug 2024 | Others | ₹1.5 Cr | Open |
| 24 Feb 2023 | Others | ₹4.89 Cr | Open |
| 24 Feb 2023 | Others | ₹3.09 Cr | Open |
| 28 Jan 2022 | Others | ₹1.81 Cr | Open |
| 07 Jan 2022 | Others | ₹24 Lakh | Open |
Total charge records: 8 View all charges
Employees and EPFO Compliance at Bruck Pharma Private Limited
Bruck Pharma Private Limited has a workforce of 123 employees as of Mar 31, 2025.
Employee Count & EPFO Data of Bruck Pharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Bruck Pharma Private Limited
GSTIN & GST Filing Data of Bruck Pharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Bruck Pharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Bruck Pharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Bruck Pharma Private Limited
MSME Payment Delays by Bruck Pharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Bruck Pharma Private Limited
Subsidiaries & Group Companies of Bruck Pharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Bruck Pharma Private Limited with ownership details.
MCA Filings & Documents of Bruck Pharma Private Limited
MCA Filings & Documents of Bruck Pharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Bruck Pharma Private Limited
Frequently Asked Questions about Bruck Pharma Private Limited
Bruck Pharma Private Limited is an active private limited company in the pharma sector based in Goregaon East, Maharashtra, India. It was incorporated on 23 August 1984 (42+ years old) and is registered under CIN U24239MH1984PTC416799. The company has 123 employees.
Bruck Pharma Private Limited reported revenue of ₹58.81 Cr for FY 2024 (up 3.00% YoY).
The current directors of Bruck Pharma Private Limited are:
The primary industry of Bruck Pharma Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Bruck Pharma Private Limited can be reached at the registered office: Office No.405 4Th Floor B Wing Cello Triumph, I B Patel Road, Goregaon East, Maharashtra, India – 400063, or through the website bruck.in.
The authorised capital is ₹5 Cr, and the paid-up capital is ₹2.68 Cr.